Johnson & Johnson sales increased 9.1% to $ 19.5 billion in the second quarter 2014

Johnson & Johnson sales increased 9.1% to $ 19.5 billion in the second quarter 2014 -

Johnson & Johnson (NYSE: JNJ) today announced sales of $ 19.5 billion for the second quarter 2014, an increase of 9.1% compared to the second quarter of 2013. operational results increased 9.4% and the negative impact of exchange is 0, 3%. Domestic sales increased 14.9%. International sales increased 4.4%, reflecting operational growth of 5.0% and a negative currency impact of 0.6%.

Net income and diluted earnings per share for the second quarter 2014 were $ 4.3 billion and $ 1.51, respectively. The second quarter results include a charge for special items after tax of about $ 0.4 billion, mainly related to increased litigation and the accumulated integration and transaction costs related to the acquisition of Synthes, Inc. . second quarter 2013 net earnings included a charge for special items after tax of approximately $ 0.5 billion as shown in the accompanying reconciliation of non-GAAP financial measures. Excluding these items, net earnings for the quarter were $ 4.8 billion and diluted earnings per share was $ 1.66, representing an increase of 11.3% and 12.2% , respectively, compared to the same period in 2013 *

. "our solid second quarter results reflect the continued success of our new product launches and the progress we have made in achieving our priorities short term, "said Alex Gorsky, President and CEO." significant progress is being made in treatment options and access to care for patients and clients worldwide. Our diversified business model, focus on long-term growth factors and talented colleagues position us well in the global market for dynamic and evolving health care. "

The Company increased its earnings forecast for the full year 2014 to 5.85 $ -. $ 5.92 per share The orientation of the Company excludes the impact of special items

global sales of consumer $ 3.7 billion for the second quarter represented an increase of 2.4% compared to the previous year, consisting of an operational increase of 3.6% and a negative impact currency of 1.2%.

domestic sales decreased 0.5% mainly due to the sale of health protection activity. international sales increased 3.9% which reflected an operational increase of 5.8% and a negative currency impact of 1.9%.

positive contributors to operational results were sales of TYLENOL ^® and MOTRIN ^® analgesics, over-the-counter medicines upper respiratory tract as well as anti-smoking aids; NEUTROGENA ^® and AVEENO ^® skin care products; baby care products; and international sales of Listerine ^® mouthwash and feminine protection products.

The pharmaceutical global sales of $ 8.5 billion for the second quarter represented an increase of 21.1% compared to the previous year on a total and operational base. Domestic sales rose 36.6%. International sales increased 6.8%, reflecting operational growth of 6.9% and a negative currency impact of 0.1%.

The results of strong sales were mainly due to new products, including OLYSIO ^® / SOVRIAD ^® (Simeprevir) for the combined treatment of chronic hepatitis C in adult patients; XARELTO ^® (rivaroxaban), an oral anticoagulant; ZYTIGA ^® (abiraterone acetate), an oral medication, once a day for use in combination with prednisone for the treatment of metastases, prostate cancer castration-resistant; INVOKANA ^® (CANAGLIFLOZIN), for the treatment of adults with type 2 diabetes; and IMBRUVICA ^® (Ibrutinib), a kinase inhibitor for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia in patients who had at least one prior therapy.

Additional contributors to the growth in operating sales were STELARA ^® (ustekinumab), a biologic approved for the treatment of moderate to severe forms of plaque psoriasis and psoriatic arthritis; REMICADE ^® (infliximab) and SIMPONI ^® / SIMPONI ^® ARIA ™ (golimumab), biological products approved for the treatment of a number of inflammatory diseases immune-mediated; INVEGA ^® SUSTENNA ^® / XEPLION ^® (paliperidone palmitate), monthly, long-acting, injectable atypical antipsychotic for the treatment of schizophrenia in adults; and PREZISTA ^® (darunavir), a treatment for HIV.

Sales results were negatively affected by the loss of exclusivity for ACIPHEX ^® (rabeprazole), a proton-pump inhibitor for gastrointestinal disorders, and CONCERTA ^® (methylphenidate HCl) for the treatment of attention deficit disorder with hyperactivity.

in the quarter, the US Food and Drug Administration (FDA) and the European Commission (EC) has approved SYLVANT ^® (siltuximab) for the treatment of patients with the disease of multicentric Castleman which are virus negative human immunodeficiency human herpesvirus-8 negative. In addition, the EC approved for VOKANAMET ^® , a fixed-dose combination therapy CANAGLIFLOZIN and immediate-release metformin hydrochloride in one tablet for the treatment of adults with type 2 diabetes; OLYSIO ^® (Simeprevir) for the treatment of adult patients genotype 1 or 4 chronic hepatitis C; and INVEGA ^® (paliperidone ER) to expand its adult indication schizophrenia to include adolescents 15 years and older.

Furthermore, additional new drug application (sNDA) has been submitted to the FDA seeking approval for Simeprevir in combination with the nucleotide analog polymerase NS5B inhibitor sofosbuvir developed by Gilead Sciences, Inc. sNDA additional were also submitted to the FDA for monthly long-acting atypical antipsychotic INVEGA ^® SUSTENNA ^® (paliperidone palmitate) for approval to treat schizoaffective disorder either as alone or in combination.

A marketing authorization application was submitted to the European Medicines Agency to expand the label for VELCADE ^® (bortezomib) to include its use in combination with rituximab , cyclophosphamide, doxorubicin and prednisone, for the treatment of adult patients with cell lymphoma previously untreated mantle.

medical devices and diagnostics sales in the world to $ 7.2 billion for the second quarter represents an increase of 0.7% compared to the previous year, consisting of an operational increase of 0, 9% and a negative currency impact of 0.2%. Domestic sales decreased 1.4%. International sales increased 2.3%, reflecting operational growth of 2.6% and a negative currency impact of 0.3%.

main contributors to the operational growth were hip and trauma products in the company Orthopaedics, Biosense Webster's electrophysiology products in cardiovascular care company, with sales of energy products in the specialized surgery business .

results in sales in the US Diabetes Care sector were negatively affected by lower prices associated with the implementation of the Medicare competitive bidding on mail order and retail in July effective 1, 2013.

in the quarter, the SABER ™ catheter PTA dilation for treatment of patients with peripheral arterial disease received FDA and CE approval.

Subsequent to the quarter, on 30 June, the Company completed the sale of its Ortho-Clinical Diagnostics to The Carlyle Group for about $ 4 billion, subject to customary adjustments.